SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Bluegreen who wrote (16457)11/20/2003 10:15:35 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
..."Among the 194 patients who remained in the trial through week 84, 67 percent (130/194) of patients achieved a PASI 75 response"...

Notice "who remained", the original group was the initial 368 subjects, therefore the PASI 75 response is 35% which it is very good indeed, but not superior to anything around (including Amevive).

At $15,000 per year is a lot of money for xomaDna, it seems serono mojo is short in Europe, ketchup anyone!

$8 in 2008